|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded (XENE, NASDAQ) |
Company Size: |
100-499 Employees In BC (100-499 Total)
100-499 In BC (100-499 Total)
|
Revenue: |
$15.60 Million CAD |
Year Founded: |
1996 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
XENON, biopharmaceutical, phenotypes, drug development, medicines
|
Profile Views: |
2,448 Company Profile Views |
|
|
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology-focused therapies to address areas of high unmet medical need, with a focus on epilepsy. A significant focus of our discovery efforts has been on human channelopathies, enabling us to develop strong capabilities in small molecule ion channel drug discovery. Our ion channel discovery capability is founded upon our understanding of the genetics of channelopathies combined with our proprietary biology and medicinal chemistry assets and know-how.
While the pharmaceutical industry has shown significant interest in channelopathies, a general inability to target ion channels selectively with a pharmaceutical agent has been a limitation to the development of more effective or safer therapeutics. We believe we have developed a core competence in identifying and developing selective small-molecule ion channel modulators, and we believe we can use this know-how to develop a pipeline of novel ion channel inhibitors for diseases in areas of high unmet medical need. In addition, we have complemented our internal discovery capabilities by identifying external product candidates that target ion channels in the CNS for the treatment of neurological conditions.
|
|
|
Date |
Type |
Amount |
Investors |
Jan 27, 2020 |
Unattributed |
$60 Million CAD |
Public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. |
Date |
Type |
Amount |
Investors |
Jan 27, 2020 |
Unattributed |
$60M CAD |
Public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. |
|
|
Want More Xenon Pharmaceuticals Inc. News? 1 2 3 4 5 6
|
Next »
|
|
|
|
|
|
Feb 23, 2021 |
Senior Informatics/Systems Analyst |
Details
|
Feb 2, 2021 |
Systems Engineer |
Details
|
Feb 2, 2021 |
IT Helpdesk Technician |
Details
|
1 - 3 of 3 results
|
|
 |
|
|
|
|
Jan 19, 2021
|
Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021
|
Dec 16, 2020
|
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs
|
Oct 9, 2020
|
Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE
|
Aug 25, 2020
|
Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer
|
Aug 13, 2020
|
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
|
May 28, 2020
|
Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
|
Mar 31, 2020
|
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 10, 2020
|
Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update
|
Jan 28, 2020
|
Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares
|
Jan 24, 2020
|
Burnaby-based Xenon Pharmaceuticals Announces Planned $60.0 Million Financing (Public Offering of Common Shares)
|
|
1 - 10 of 71 results
|
|
 |
|
|
|
Share This Company Profile |
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|